Form 4: Moderna Director Nader Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Director Francois Nader reports acquisition of stock options and restricted stock units in Moderna, Inc.
Summary
- On April 30, 2025, Francois Nader, a director of Moderna, Inc., acquired 6,378 stock options with an exercise price of $28.54.
- These options vest fully on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, contingent upon continued service.
- Nader also acquired 12,174 restricted stock units (RSUs) that convert into common stock on a one-for-one basis.
- These RSUs vest fully on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, contingent upon continued service.
- Following these transactions, Nader directly owns 6,378 stock options and 12,174 RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions, which doesn't inherently suggest positive or negative implications for the company's performance.
Positives
- The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.
- Vesting schedules, such as the one described in the document (vesting on the earlier of a specific date or the next annual meeting), are typical in these types of grants.
Stakeholder Impact
- The acquisition of stock options and RSUs by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date of transaction: acquisition of stock options and restricted stock units. |
| 04/30/2026 | Vesting date for stock options and restricted stock units, or earlier if Moderna's next Annual Meeting of Shareholders occurs before this date. |
| 04/30/2035 | Expiration date for the acquired stock options. |
| 05/01/2025 | Date of signature for the Form 4 filing. |
Keywords
Moderna, Director, Nader, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.